Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
2.
J Plast Reconstr Aesthet Surg ; 67(9): e223-5, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25052183

ABSTRACT

Surgical resection is the definitive treatment modality for basal cell carcinoma (BCC). However, not all patients may be suitable for surgery. We describe a patient with a BCC, which resolved clinically and histologically when he underwent systemic R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) for treatment of a high grade B-cell lymphoma. Although topical and intra-lesional 5-fluorouracil (5-FU) has been used as an adjunct to treatment, more recent reports have illustrated the treatment of BCC with systemic 5-FU in combination with bleomycin and cisplatin. We postulate that the combination of cyclophosphamide and doxorubicin with rituximab and prednisolone, which has not been previously reported in the literature, contributed to remission in this case.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Basal Cell/drug therapy , Carcinoma, Basal Cell/surgery , Lymphoma, B-Cell/drug therapy , Nose Neoplasms/drug therapy , Nose Neoplasms/surgery , Aged , Antibodies, Monoclonal, Murine-Derived/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Combined Modality Therapy/methods , Cyclophosphamide/administration & dosage , Doxorubicin/administration & dosage , Humans , Induction Chemotherapy/methods , Lymphoma, B-Cell/pathology , Male , Prednisone/administration & dosage , Rituximab , Vincristine/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...